A detailed history of Sjs Investment Consulting Inc. transactions in Alkermes Plc. stock. As of the latest transaction made, Sjs Investment Consulting Inc. holds 23 shares of ALKS stock, worth $691. This represents 0.0% of its overall portfolio holdings.

Number of Shares
23
Previous 18 27.78%
Holding current value
$691
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 16, 2024

BUY
$23.01 - $28.55 $115 - $142
5 Added 27.78%
23 $0
Q2 2024

Jul 16, 2024

BUY
$23.21 - $27.24 $371 - $435
16 Added 800.0%
18 $0
Q4 2023

Jan 16, 2024

BUY
$23.37 - $28.68 $46 - $57
2 New
2 $0
Q4 2022

Jan 23, 2023

SELL
$21.94 - $26.24 $285 - $341
-13 Closed
0 $0
Q3 2022

Oct 13, 2022

BUY
$22.0 - $31.87 $220 - $318
10 Added 333.33%
13 $0
Q1 2022

May 05, 2022

BUY
$23.07 - $27.99 $69 - $83
3 New
3 $0

Others Institutions Holding ALKS

About Alkermes plc.


  • Ticker ALKS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 164,254,000
  • Market Cap $4.94B
  • Description
  • Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...
More about ALKS
Track This Portfolio

Track Sjs Investment Consulting Inc. Portfolio

Follow Sjs Investment Consulting Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sjs Investment Consulting Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sjs Investment Consulting Inc. with notifications on news.